← argenx NV ADR overview

argenx NV ADR vs Abcellera Biologics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

argenx NV ADR (ARGX)

Q3 2026
▲2

argenx beats on strong sales, buys Forte to expand pipeline

  • Q2 earnings beat with 60% sales growth argenx reported Q2 GAAP EPS of $7.32, beating estimates by $1.12, with revenue up 60% to $1.52 billion. Cash flow turned positive and cash rose to $5.2 billion. This shows the core business is growing fast and generating cash, which supports a higher stock price.

    This is the main new financial result that directly shows the company's strong performance and supports the stock.

  • VYVGART label expanded and pipeline milestones ahead argenx launched an expanded U.S. label for VYVGART covering all serotypes of generalized myasthenia gravis. It also expects key trial results in autoimmune myositis and multifocal motor neuropathy later this year. These could open new markets and drive future sales growth.

    This points to future growth drivers beyond the current quarter, which investors care about for the long-term story.

  • Acquiring Forte Biosciences for $2.2 billion in cash argenx agreed to buy Forte Biosciences for $77 per share, or about $2.2 billion in cash, adding a first-in-class antibody for vitiligo and celiac disease. The deal uses cash reserves but could strengthen the pipeline. The stock may react to the cost versus the potential new treatment.

    This is a major strategic move that affects the company's cash and future pipeline, directly influencing the investment case.

July 2026
▲2

argenx beats on strong sales, buys Forte to expand pipeline

  • Q2 earnings beat with 60% sales growth argenx reported Q2 GAAP EPS of $7.32, beating estimates by $1.12, with revenue up 60% to $1.52 billion. Cash flow turned positive and cash rose to $5.2 billion. This shows the core business is growing fast and generating cash, which supports a higher stock price.

    This is the main new financial result that directly shows the company's strong performance and supports the stock.

  • VYVGART label expanded and pipeline milestones ahead argenx launched an expanded U.S. label for VYVGART covering all serotypes of generalized myasthenia gravis. It also expects key trial results in autoimmune myositis and multifocal motor neuropathy later this year. These could open new markets and drive future sales growth.

    This points to future growth drivers beyond the current quarter, which investors care about for the long-term story.

  • Acquiring Forte Biosciences for $2.2 billion in cash argenx agreed to buy Forte Biosciences for $77 per share, or about $2.2 billion in cash, adding a first-in-class antibody for vitiligo and celiac disease. The deal uses cash reserves but could strengthen the pipeline. The stock may react to the cost versus the potential new treatment.

    This is a major strategic move that affects the company's cash and future pipeline, directly influencing the investment case.

Latest
▲2

argenx beats on strong sales, buys Forte to expand pipeline

  • Q2 earnings beat with 60% sales growth argenx reported Q2 GAAP EPS of $7.32, beating estimates by $1.12, with revenue up 60% to $1.52 billion. Cash flow turned positive and cash rose to $5.2 billion. This shows the core business is growing fast and generating cash, which supports a higher stock price.

    This is the main new financial result that directly shows the company's strong performance and supports the stock.

  • VYVGART label expanded and pipeline milestones ahead argenx launched an expanded U.S. label for VYVGART covering all serotypes of generalized myasthenia gravis. It also expects key trial results in autoimmune myositis and multifocal motor neuropathy later this year. These could open new markets and drive future sales growth.

    This points to future growth drivers beyond the current quarter, which investors care about for the long-term story.

  • Acquiring Forte Biosciences for $2.2 billion in cash argenx agreed to buy Forte Biosciences for $77 per share, or about $2.2 billion in cash, adding a first-in-class antibody for vitiligo and celiac disease. The deal uses cash reserves but could strengthen the pipeline. The stock may react to the cost versus the potential new treatment.

    This is a major strategic move that affects the company's cash and future pipeline, directly influencing the investment case.

Abcellera Biologics Inc (ABCL)

Q3 2026
▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

  • Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.

    This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.

  • Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.

    This is a new financial report showing deteriorating results, which weighs on the stock price.

  • ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.

    This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

July 2026
▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

  • Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.

    This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.

  • Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.

    This is a new financial report showing deteriorating results, which weighs on the stock price.

  • ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.

    This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

Latest
▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

  • Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.

    This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.

  • Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.

    This is a new financial report showing deteriorating results, which weighs on the stock price.

  • ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.

    This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

© 2026 MarketIVWhy